{"id":"NCT05067335","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-21","primaryCompletion":"2023-11-09","completion":"2023-11-09","firstPosted":"2021-10-05","resultsPosted":"2024-12-05","lastUpdate":"2024-12-05"},"enrollment":327,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis"],"interventions":[{"type":"DRUG","name":"Romosozumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Romosozumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in bone mineral density (BMD) at the lumbar spine, at the total hip and femoral neck in postmenopausal Chinese women with osteoporosis.","primaryOutcome":{"measure":"Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine to the End of Double-Blind Period","timeFrame":"From Baseline (Day 1) to the end of the Double-blind Period (Month 6)","effectByArm":[{"arm":"Placebo","deltaMin":0.44,"sd":0.442},{"arm":"Romosozumab","deltaMin":9.81,"sd":0.323}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"55 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":30,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":109},"commonTop":["COVID-19","Suspected COVID-19","Upper respiratory tract infection","Injection site reaction","Arthralgia"]}}